

# Lawrence Mayer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11072844/publications.pdf>

Version: 2024-02-01

6  
papers

368  
citations

1937685

4  
h-index

1872680

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

620  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 30, 102275.	3.3	15
2	CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML. <i>Leukemia Research</i> , 2018, 74, 121-129.	0.8	4
3	Passive and semi-active targeting of bone marrow and leukemia cells using anionic low cholesterol liposomes. <i>Journal of Drug Targeting</i> , 2016, 24, 797-804.	4.4	24
4	Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations. <i>Chemotherapy Research and Practice</i> , 2011, 2011, 1-7.	1.6	17
5	In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. <i>Leukemia Research</i> , 2009, 33, 129-139.	0.8	305
6	Phase I Study of a Liposomal Carrier (CPX-351) Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias and Myelodysplastic Syndromes (MDS).. <i>Blood</i> , 2007, 110, 900-900.	1.4	3